Novo’s obesity drug reduces risk of diabetes
Novo Nordisk presented very uplifting data for its obesity drug Saxenda late last week, showing that the drug can both delay and prevent the onset of type 2 diabetes.
BY STEFAN SINGH KAILAY
Novo Nordisk announced headline results from the Scale three-year extension trial in adults with obesity or who were overweight with comorbidities and had prediabetes at baseline late last week. And the results are welcome news to the Danish-based biopharma group.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo launches obesity drug in the US
For abonnenter
Novo wins approval of obesity drug in Europe
For abonnenter
